Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?

Research output: Contribution to journalArticle

Abstract

In a multicenter, observational, propensity-score-weighted cohort of 249 adults with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 days; interquartile range [IQR], 8-10) therapy had a similar odds of recurrent infection or death within 30 days as those receiving longer courses (median, 16 days; IQR, 14-17).

Original languageEnglish (US)
Pages (from-to)2011-2014
Number of pages4
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume69
Issue number11
DOIs
StatePublished - Nov 13 2019

Fingerprint

Propensity Score
Bacteremia
Pseudomonas aeruginosa
Anti-Bacterial Agents
Infection
Therapeutics

Keywords

  • Pseudomonas aeruginosa
  • cefepime
  • gram-negative bacteremia
  • piperacillin-tazobactam
  • treatment duration

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{3b920e04a5d0494997765ca52cb6ef62,
title = "Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?",
abstract = "In a multicenter, observational, propensity-score-weighted cohort of 249 adults with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 days; interquartile range [IQR], 8-10) therapy had a similar odds of recurrent infection or death within 30 days as those receiving longer courses (median, 16 days; IQR, 14-17).",
keywords = "Pseudomonas aeruginosa, cefepime, gram-negative bacteremia, piperacillin-tazobactam, treatment duration",
author = "Valeria Fabre and Joe Amoah and Cosgrove, {Sara E.} and Tamma, {Pranita D.}",
year = "2019",
month = "11",
day = "13",
doi = "10.1093/cid/ciz223",
language = "English (US)",
volume = "69",
pages = "2011--2014",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections

T2 - How Long Is Long Enough?

AU - Fabre, Valeria

AU - Amoah, Joe

AU - Cosgrove, Sara E.

AU - Tamma, Pranita D.

PY - 2019/11/13

Y1 - 2019/11/13

N2 - In a multicenter, observational, propensity-score-weighted cohort of 249 adults with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 days; interquartile range [IQR], 8-10) therapy had a similar odds of recurrent infection or death within 30 days as those receiving longer courses (median, 16 days; IQR, 14-17).

AB - In a multicenter, observational, propensity-score-weighted cohort of 249 adults with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 days; interquartile range [IQR], 8-10) therapy had a similar odds of recurrent infection or death within 30 days as those receiving longer courses (median, 16 days; IQR, 14-17).

KW - Pseudomonas aeruginosa

KW - cefepime

KW - gram-negative bacteremia

KW - piperacillin-tazobactam

KW - treatment duration

UR - http://www.scopus.com/inward/record.url?scp=85074965214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074965214&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz223

DO - 10.1093/cid/ciz223

M3 - Article

C2 - 30882137

AN - SCOPUS:85074965214

VL - 69

SP - 2011

EP - 2014

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -